BrightSpring Health Services, Inc.
No SEC Form 4 filings for $BTSG in the last 30 days.
See all $BTSG insider activity →Zacks says BrightSpring Health Services (BTSG) has growth momentum in Provider Services and Pharmacy Solutions, citing Q2 2026 Pharmacy Solutions revenue up 30% YoY to $2.9B and Provider Services up 30% to $466M. It also flags IRA reimbursement pressure, estimating about $50M impact in Q2 2026 and ~$200M full-year. BTSG shares are up 54.6% YTD; forward P/E 41.80.
BrightSpring Health Services (BTSG) reported Q2 2026 net revenue of $3.873B, up 23%, and adjusted EBITDA of $205.5M, up 44.2%, with adjusted EPS of $0.45. FY2026 guidance raised to $15.1B-$15.425B revenue and $820M-$845M adjusted EBITDA. Net debt was $1.7B (2.15x leverage).
BrightSpring Health Services (BTSG) reported Q2 revenue of $3.87B vs $3.66B expected and adjusted EPS of $0.45 vs $0.40, with adjusted EBITDA of $205.5M. The company raised full-year revenue guidance to $15.26B and EBITDA guidance to $832.5M. Management cited 30% Specialty and Infusion revenue growth and 31% script growth, while Home and Community Pharmacy faced customer exits and regulatory headwinds.
Over the past 7 days, alphai's AI scored 1 news story mentioning BTSG (BrightSpring Health Services, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent BTSG coverage spans earnings and financial news.
The article frames a near-term earnings/margin risk from IRA reimbursement resets and pharmacy customer exits, partially offset by strong specialty and infusion growth plus improving EBITDA conversion.
Guidance and segment growth details suggest improving profitability trajectory, but IRA-driven pharmacy headwinds and Home and Community Pharmacy declines remain key risk variables.
Guidance lift and strong Specialty and Infusion growth are positives, but analyst questions highlight margin pressure in Pharmacy and ongoing regulatory/customer-exit headwinds.
Guidance raise and margin expansion support a bullish re-rating, but IRA reimbursement pressure and integration costs cap upside.
The article frames a strong earnings print and raised guidance against a high forward multiple, implying upside depends on continued margin and script execution.
alphai scores every news story that mentions BTSG with an AI model for sentiment and relevance, and aggregates insider trades from BrightSpring Health Services, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Zacks says BrightSpring Health Services (BTSG) has growth momentum in Provider Services and Pharmacy Solutions, citing Q2 2026 Pharmacy Solutions revenue up 30% YoY to $2.9B and Provider Services up 30% to $466M. It also flags IRA reimbursement pressure, estimating about $50M impact in Q2 2026 and ~$200M full-year. BTSG shares are up 54.6% YTD; forward P/E 41.80.
7 min readBrightSpring Health Services (BTSG) reported Q2 2026 net revenue of $3.873B, up 23%, and adjusted EBITDA of $205.5M, up 44.2%, with adjusted EPS of $0.45. FY2026 guidance raised to $15.1B-$15.425B revenue and $820M-$845M adjusted EBITDA. Net debt was $1.7B (2.15x leverage).
6 min readBrightSpring Health Services (BTSG) reported Q2 revenue of $3.87B vs $3.66B expected and adjusted EPS of $0.45 vs $0.40, with adjusted EBITDA of $205.5M. The company raised full-year revenue guidance to $15.26B and EBITDA guidance to $832.5M. Management cited 30% Specialty and Infusion revenue growth and 31% script growth, while Home and Community Pharmacy faced customer exits and regulatory headwinds.
6 min readBrightSpring Health Services (BTSG) beat Q2 expectations with adjusted EPS of 45 cents (21.6% above consensus) and revenue of $3.87B (+23% YoY). It raised 2026 guidance to $15.10-$15.425B revenue and $820-$845M adjusted EBITDA. Specialty and infusion grew 30.1% and home health revenues rose 30.3%, while pharmacy fell 8% due to IRA impacts.
6 min readBrightSpring Health Services (BTSG) reported Q2 revenues of $3.87B, up 23% YoY, and adjusted EPS of 45 cents, up 104.5%, beating Zacks estimates, and raised its full-year outlook. The article cites gross margin at 12.7% (+80 bps) and operating margin up 180 bps. It notes forward P/E of 30.7x and expects IRA reimbursement impacts of about $45M per quarter in 2026.
6 min readBrightSpring Health Services (BTSG) shares fell 18.1% over the past week after better-than-expected Q2 results and raised guidance. Q2 revenue rose 23% to $3.87B and adjusted EPS rose 104.5% to 45 cents. 2026 guidance was raised to $15.1-$15.425B revenue and $820-$845M adjusted EBITDA, but investors cited valuation risk and policy-driven reimbursement pressure.
6 min readSimply Wall St reports BrightSpring Health Services (BTSG) posted Q2 2026 revenue of $3.87B and net income of $84.29M, with higher EPS year over year. The company raised full-year 2026 revenue guidance to $15.10B-$15.43B. The piece discusses implications for its long-term growth and margin outlook.
7 min readBrightSpring Health Services (NASDAQ: BTSG) shares fell 17.5% after the company reported Q2 revenue up 23% to $3.87B and non-GAAP EPS of $0.45, alongside higher full-year guidance. Despite the beat and raise, investors reacted negatively, citing valuation and stagnant profit margins.
3 min readBrightSpring Health Services (BTSG) reported Q2 2026 net income of $84.29M versus $28.21M a year earlier. Revenue rose to $3.87B from $3.15B. EPS from continuing operations increased to $0.39 from $0.04, and adjusted EPS to $0.45 from $0.22. Adjusted EBITDA rose to $205.51M from $142.52M. The company raised FY2026 guidance for revenue to $15.10B-$15.43B and adjusted EBITDA to $820M-$845M.
2 min readHealthcare services provider BrightSpring Health Services (NASDAQ: BTSG) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 23% year on year to $3.87 billion. The company’s full-year revenue guidance of $15.26 billion at the midpoint came in 1.3% above analysts’ estimates. Its non-GAAP profit of $0.45 per share was 13% above analysts’ consensus estimates. Is now the time to buy BrightSpring Health Services?
6 min read
